Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry

Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis

(2012) W. Rathmann et al.   DIABETES OBESITY & METABOLISM

Comorbidity, hypoglycaemia and appropriate selection of antidiabetic pharmacotherapy in diabetic patients with heart failure in clinical practice in Germany

(2012) A.K. Gitt et al.   HERZ

Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients - an analysis of the DiaRegis registry

(2011) Diethelm Tschöpe et al.   Cardiovascular Diabetology

Hypoglycaemia is more frequent in type 2 diabetic patients with co-morbid vascular disease: an analysis of the DiaRegis registry

(2011) Anselm K Gitt et al.   European Journal of Preventive Cardiology

Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline

(2010) Peter Bramlage et al.   Cardiovascular Diabetology

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

(2010) D. R. Matthews et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial

(2010) R. Arechavaleta et al.   DIABETES OBESITY & METABOLISM

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study

(2010) C. Filozof et al.   DIABETIC MEDICINE

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes

(2010) T. Forst et al.   DIABETIC MEDICINE

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

(2010) T. Seck et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial

(2010) B. Göke et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Tailoring treatment to the individual in type 2 diabetes practical guidance from theGlobal Partnership for Effective Diabetes Management

(2010) S. Del Prato et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Implications of Postprandial Glucose and Weight Control in People With Type 2 Diabetes: Understanding and implementing the International Diabetes Federation guidelines

(2009) B. Gallwitz   DIABETES CARE

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

(2009) E. Ferrannini et al.   DIABETES OBESITY & METABOLISM

Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus

(2009) S. Matthaei et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE

Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes

(2007) C. V. Asche et al.   DIABETES OBESITY & METABOLISM